

| | | |
|--|---|-------------------------|
| FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Atty. Docket No. X-15876 | Serial No 10/526,960 |
| | First Applicant Maria-Jesus Blanco-Pillado | |
| | PCT Application Date: September 17, 2003 | Group Art Unit 1624 |
| | US Nat'l Entry Date: March 3, 2005 | |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. 1 | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear |
|--------------------|------------|---|--------------------------------|--|---|
| | AC | US 4,191,771 | March 4, 1980 | Zimmerman | |
| | AD | US 4,891,379 | January 2, 1990 | Zimmerman, et al. | |
| | AE | US 6,140,352 | October 31, 2000 | Crowell, et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. 1 | Foreign Patent Document Country Code ³ -Number 4- Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|------------|--|--------------------------------|--|---|----------------|
| | BI | EP 1 072 592 | 31 January 2001 | Pfizer, Inc. | | |
| | BJ | WO 02/078693 | 10 October 2002 | Eli Lilly and Company | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. 1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published. | T ⁶ |
|--------------------|------------|--|----------------|
| | CA | Wentland, et al., "8-Carboxamidocyclazocine Analogues: Redefining the Structure-Activity Relationships of 2,6-Methano-3-Benzazocines," <u>Bioorganic & Medicinal Chemistry Letters</u> , Vol. 11, pgs. 623-626 (2001) | |
| | CB | Wentland, et al., "3-Carboxamido Analogues of Morphine and Naltrexone: Synthesis and Opioid Receptor Binding Properties," <u>Bioorganic & Medicinal Chemistry Letters</u> , Vol. 11, pgs. 1717-1721 (2001) | |
| | CC | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols is indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2-3 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.